@article{8256bf32efb64aadb34872f9001998c2,
title = "Basics on the use of acid-sensing ion channels' inhibitors as therapeutics",
abstract = "Since the discovery of acid-sensing ion channels in 1997, their importance in the health of neurons and other non-neuronal cells has gained significant importance. Acid-sensing ion channels play important roles in mediating pain sensation during diseases such as stroke, inflammation, arthritis, cancer, and recently migraine. More interestingly, acid-sensing ion channels may explain the sex differences in pain between males and females. Also, the ability of acid-sensing ion channel blockers to exert neuroprotective effects in a number of neurodegenerative diseases has added a new dimension to their therapeutic value. The current failure rate of ∼45% of new drugs (due to toxicity issues) and saving of up to 7 years in the life span of drug approval makes drug repurposing a high priority. If acid-sensing ion channels' blockers undergo what is known as {"}drug repurposing{"}, there is a great potential to bring them as medications with known safety profiles to new patient populations. However, the route of administration remains a big challenge due to their poor penetration of the blood brain and retinal barriers. In this review, the promise of using acid-sensing ion channel blockers as neuroprotective drugs is discussed.",
keywords = "acid, calpain, glaucoma, ion channel, neurodegeneration, neuroprotection, optic nerve, sensing",
author = "Jamileh Dibas and Houssam Al-Saad and Adnan Dibas",
note = "Funding Information: This study was supported by the National Natural Science Foundation of China, No. 81772321 (to HZL), 81571194 (to HZL), 81471277 (to JGH); a grant from the Key Program of Anhui Province for Outstanding Talents in Universities in China, No. gxbjZD2016071 (to HZL), 2014H012 (to HZL). The funding sources had no role in study conception and design, data analysis or interpretation, paper writing or deciding to submit this paper for publication. Funding Information: Author contributions: Article writing: JD, HAS and AD. Conflicts of interest: None declared. Financial support: This work was supported by the BrightFocus Foundation and intramural grant from University of North Texas Health Science Center at Fort Worth (to AD). Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication. Plagiarism check: Checked twice by iThenticate. Peer review: Externally peer reviewed. Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. Open peer reviewer: Steven Levy, MD Stem Cells, USA. Additional file: Open peer review report 1. Funding Information: Funding: This work was supported by the BrightFocus Foundation and intramural grant from North Texas Health Science Center at Fort Worth (to AD). Publisher Copyright: {\textcopyright} 2019 Medknow Publications. All rights reserved.",
year = "2019",
month = mar,
doi = "10.4103/1673-5374.245466",
language = "English",
volume = "14",
pages = "395--398",
journal = "Neural Regeneration Research",
issn = "1673-5374",
publisher = "Wolters Kluwer Medknow Publications",
number = "3",
}